JP2014524480A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524480A5
JP2014524480A5 JP2014527329A JP2014527329A JP2014524480A5 JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5 JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
active agent
formulation
pharmaceutical
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014527329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524480A (ja
JP6169079B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/052304 external-priority patent/WO2013028989A1/en
Publication of JP2014524480A publication Critical patent/JP2014524480A/ja
Publication of JP2014524480A5 publication Critical patent/JP2014524480A5/ja
Application granted granted Critical
Publication of JP6169079B2 publication Critical patent/JP6169079B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014527329A 2011-08-24 2012-08-24 徐放のための活性剤の製剤 Active JP6169079B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161526940P 2011-08-24 2011-08-24
US61/526,940 2011-08-24
US201161551506P 2011-10-26 2011-10-26
US61/551,506 2011-10-26
PCT/US2012/052304 WO2013028989A1 (en) 2011-08-24 2012-08-24 Formulations of active agents for sustained release

Publications (3)

Publication Number Publication Date
JP2014524480A JP2014524480A (ja) 2014-09-22
JP2014524480A5 true JP2014524480A5 (enExample) 2015-10-15
JP6169079B2 JP6169079B2 (ja) 2017-07-26

Family

ID=47746903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527329A Active JP6169079B2 (ja) 2011-08-24 2012-08-24 徐放のための活性剤の製剤

Country Status (7)

Country Link
US (2) US20130084277A1 (enExample)
EP (2) EP2747832A4 (enExample)
JP (1) JP6169079B2 (enExample)
CN (1) CN104023784B (enExample)
CA (1) CA2846209C (enExample)
HK (1) HK1199418A1 (enExample)
WO (1) WO2013028989A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3220936A4 (en) * 2014-11-21 2018-08-22 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
ES2822598T3 (es) 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102646323B1 (ko) 2016-05-06 2024-03-13 이뮤노포지 주식회사 제어된 지속 방출을 위한 elp 융합 단백질
CN119390817A (zh) * 2024-10-14 2025-02-07 华南理工大学 一种可编程的多重修饰长效缓释类弹性蛋白elp载体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
EP3725299A1 (en) * 2005-06-24 2020-10-21 Duke University A direct drug delivery system based on thermally responsive biopolymers
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1971355B1 (en) * 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) * 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
CN101578373A (zh) * 2006-09-06 2009-11-11 费斯生物制药公司 融合肽治疗组合物
AU2008262031B2 (en) * 2007-06-08 2011-08-25 Boehringer Ingelheim International Gmbh Extended release formulation of nevirapine
EP2190872B1 (en) * 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN105727261A (zh) * 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
IN2012DN02120A (enExample) * 2009-08-14 2015-08-21 Phasebio Pharmaceuticals Inc
ES2669190T3 (es) * 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión

Similar Documents

Publication Publication Date Title
AU2023237119B2 (en) Buffered formulations of exendin (9-39)
ES2992698T3 (en) Combination of an insulin and a glp-1 agonist
US20250000933A1 (en) Terlipressin compositions and their methods of use
CA2814057C (en) Intravenous composition comprising paracetamol and ibuprofen
CA2846209C (en) Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2018528242A (ja) 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法
JP2022502432A5 (enExample)
ES3062720T3 (en) Sublingual epinephrine tablets
JP2020500864A5 (enExample)
CN110678194A (zh) 奥曲肽注射液
JP2009506978A5 (enExample)
Hughes IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
EP4536691A1 (en) Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
JP2020510028A5 (enExample)
JP2014502608A5 (enExample)
JP2008505087A5 (enExample)
CN114096269A (zh) 高浓度胰岛素制剂
JP2007513059A5 (enExample)
Kesavadev et al. Newer insulins on the horizon
HK40014065A (en) Terlipressin composition for use in treating ascites
HK40014065B (en) Terlipressin composition for use in treating ascites